3763-80-2

Basic information

• Product Name: 3-(2-chloro-10H-phenothiazin-10-yl)propan-1-amine
• Synonyms: 10H-phenothiazine-10-propanamine, 2-chloro-; 2-Chloro-10-(3-aminopropyl)phenothiazine
• CAS NO: 3763-80-2
• Molecular Formula: C₁₅H₁₅ClN₂S*ClH
• Molecular Weight: 290.811
• Mol File: 3763-80-2.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 456.5°C at 760 mmHg
• Flash Point: 229.9°C
• Density: 1.284g/cm³
• Vapor Pressure: 1.61E-08mmHg at 25°C
• Refractive Index: 1.657
• CAS DataBase Reference: 3-(2-chloro-10H-phenothiazin-10-yl)propan-1-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(2-chloro-10H-phenothiazin-10-yl)propan-1-amine(3763-80-2)
• EPA Substance Registry System: 3-(2-chloro-10H-phenothiazin-10-yl)propan-1-amine(3763-80-2)

Safety Data

• Hazardous Substances Data: 3763-80-2(Hazardous Substances Data)

Usage

General Description

3-(2-chloro-10H-phenothiazin-10-yl)propan-1-amine is a chemical compound that belongs to the class of phenothiazine derivatives. It is a psychoactive drug that is used as an antipsychotic medication to treat schizophrenia and other mental disorders. The compound works by antagonizing dopamine receptors in the brain, thereby reducing the symptoms of psychosis. It also has antiemetic and anti-anxiety properties, making it useful in the treatment of nausea and anxiety disorders. The compound is typically administered orally or intravenously and is sold under the brand name promazine. However, it can also have a range of side effects, including sedation, dizziness, and low blood pressure, and should be used with caution.

Upstream product

• 92-39-7 2-chlorophenothiazine 
• 180388-71-0 N-[3-(2-chloro-phenothiazin-10-yl)-propyl]-phthalimide 

Downstream Products

• 1423077-24-0 4-chloro-N-(3-(2-chloro-10H-phenothiazin-10-yl)propyl)benzenesulfonamide 
• 1423077-22-8 N-(3-(2-chloro-10H-phenothiazin-10-yl)propyl)-4-cyanobenzenesulfonamide 
• 1423077-16-0 N-(3-(2-chloro-10H-phenothiazin-10-yl)propyl)-4-methoxybenzenesulfonamide 
• 96068-57-4 1-[3-(2-chloro-phenothiazin-10-yl)-propyl]-5-ethyl-5-phenyl-pyrimidine-2,4,6-trione 
• 96178-10-8 5-ethyl-1-(3-phenothiazin-10-yl-propyl)-5-phenyl-pyrimidine-2,4,6-trione 
• 22724-19-2 N-[3-(2-chloro-phenothiazin-10-yl)-propyl]-N-(toluene-4-sulfonyl)-acetamide 
• 19077-27-1 N-(3-(2-chloro-10H-phenothiazin-10-yl)propyl)-4-methylbenzenesulfonamide 

Relevant articles and documents

Reengineered tricyclic anti-cancer agents

The phenothiazine and dibenzazepine tricyclics are potent neurotropic drugs with a documented but underutilized anti-cancer side effect. Reengineering these agents (TFP, CPZ, CIP) by replacing the basic amine with a neutral polar functional group (e.g., RTC-1, RTC-2) abrogated their CNS effects as demonstrated by in vitro pharmacological assays and in vivo behavioral models. Further optimization generated several phenothiazines and dibenzazepines with improved anti-cancer potency, exemplified by RTC-5. This new lead demonstrated efficacy against a xenograft model of an EGFR driven cancer without the neurotropic effects exhibited by the parent molecules. Its effects were attributed to concomitant negative regulation of PI3K-AKT and RAS-ERK signaling.